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Chemotherapy drugs 
cyclophosphamide, cisplatin and 
doxorubicin induce germ cell loss in 
an in vitro model of the prepubertal 
testis
Ellie Smart  1,3, Federica Lopes1, Siobhan Rice1,4, Boglarka Nagy1, Richard A. Anderson  2, 
Rod T. Mitchell  2 & Norah Spears1
Long term survival rates for childhood cancers is steadily increasing, however cancer survivors can 
experience fertility problems as a consequence of chemotherapy treatment. This is particularly 
problematic for young boys, for whom no fertility preservation treatment is yet established. Here, we 
have determined the effects on prepubertal mouse testis of three commonly used chemotherapy drugs; 
cyclophosphamide (using its active metabolite phosphoramide mustard), cisplatin and doxorubicin, 
exposing testicular fragments to a clinically relevant range of concentrations in vitro. All three drugs 
induced a specific and highly significant loss of germ cells, including spermatogonial stem cells. In 
contrast, there was no significant effect on somatic cells, for either Sertoli or interstitial cells. Time 
course analysis of cleaved Caspase-3 expression showed a significant increase in apoptosis eight hours 
prior to a detectable decrease in germ cell numbers following exposure to phosphoramide mustard 
or cisplatin, although this pattern was not seen following doxorubicin-exposure. Moreover, analysis 
of DNA damage at 16 h showed increased γH2AX expression in response to all three drugs. Overall, 
results show that cisplatin, doxorubicin and cyclophosphamide all specifically induce loss of germ cells, 
including of spermatogonial stem cells, in the prepubertal mouse testis at concentrations relevant to 
human therapeutic exposures.
Survival rates from most childhood cancers have increased dramatically over recent decades, with chemotherapy 
a mainstay of treatment for the majority of these patients. Ideally, chemotherapeutic agents would specifically 
target cancerous cells without affecting healthy tissue, however in practice there are many off-target effects of 
cytotoxic treatments, including on the gonads. There is now a growing population of cancer survivors suffering 
from chemotherapy-induced infertility with some also affected by hypogonadism, effects that can significantly 
impact on quality of life. The situation is of particular concern for male childhood cancer patients due to the lack 
of fertility preservation methods available for prepubertal males1.
Prepuberty in humans can be defined as the period from late infancy until the onset of puberty: during this 
period there is relatively little testicular activity, with low rates of proliferation within the spermatogonial germ 
cell and Sertoli cell populations compared to the frequent proliferation that occurs in these cells during infancy 
and adulthood2,3. Although occasional germ cells enter meiosis during prepuberty, these cells subsequently 
undergo apoptosis4. Of particular importance during the prepubertal period is the quiescence of the HPG axis 
with very low levels of gonadotrophins and testosterone2,3,5. The comparative quiescence of the prepubertal testis 
was once thought to confer protection from chemotherapy-induced damage6. However, males treated before 
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puberty may present in adulthood with oligo- or azoospermia, with the extent of damage to the seminiferous 
epithelium related to both drug regimen and cumulative dose received7. Such damage might be related to the 
activity that takes place in the prepubertal testis, such as Sertoli cell maturation or germ cell proliferation4,8. 
Despite the clear evidence that chemotherapy drug exposure to prepubertal boys can affect subsequent fertility9, 
there is little information as to how these drugs damage the prepubertal testis. Given that the prepubertal testis 
tissue, germ cell stages and hormonal environment is markedly different from that of the pubertal or adult testis, 
it cannot be assumed that drug effects will be similar at both stages. Thus, a fuller understanding of how germ cells 
in the prepubertal testis are lost or damaged by specific chemotherapy drugs is vital for the provision of accurate 
advice and for the development of preventative treatments to protect fertility in these patients. It is also important 
to determine effects of these drugs specifically on the stem germ cell population, since survival of a sufficient 
number of spermatogonial stem cells (SSCs) allows for the possibility of subsequent germ cell repopulation of the 
testis, with the potential to restore fertility.
Here, we examine the individual effects of three different chemotherapeutic agents: cyclophosphamide (CYP); 
cisplatin (CIS); and doxorubicin (DOX). These three drugs were chosen as they are all commonly used in the 
treatment of a range of prepubertal cancers, thus with more clinical information available, including that of 
patient serum concentrations. CYP is an alkylating agent that is metabolised in the liver to a number of com-
pounds, the most active of which is phosphoramide mustard (PM). PM binds an alkyl molecule to DNA, forming 
an adduct that prevents DNA replication10. It is widely believed that alkylating agents are the most gonado-
toxic chemotherapy drugs, and that the degree of gonadal damage can be related to the dose of alkylating agent 
received11. CIS is one of several platinum-based chemotherapy drugs, all considered to act in an alkylating-like 
manner, but in which it is the platinum core that binds to DNA to form the adducts12. The action of the anthracy-
cline DOX is somewhat different, as it intercalates with DNA, inhibiting Topoisomerase II and hence preventing 
replication13. DOX is often considered to be the least gonadotoxic of the agents examined here, only causing 
prolonged azoospermia when combined with other drugs14.
We aimed to determine the effects of exposure to each of PM, CIS or DOX on prepubertal testis within a 
clinically-relevant range of concentrations. We utilised an in vitro culture system of prepubertal mouse testis 
tissue which we have previously demonstrated to support short-term development of the prepubertal mouse 
testis15. This stage of development in rodents has important similarities to the human during prepuberty in 
terms of relative quiescence of the hypothalamic-pituitary-gonadal (HPG) axis and the presence of a germ cell 
population consisting almost exclusively of spermatogonia4,5. However, when determining potential relevance 
to humans there are also key species differences that should be considered such as the precise spermatogonial 
sub-populations and rates of Sertoli cell proliferation3,4,16. Using this system we were able to examine the direct 
effects of each drug, and to provide a comparison of relative gonadotoxicity between drugs. Exposure to each of 
the three chemotherapeutic agents resulted in a significant reduction in germ cell number, which include the 
promyelocytic leukemia zinc-finger-positive (PLZF+) SSC sub-population.
Results
Cyclophosphamide, cisplatin and doxorubicin each result in a specific loss of germ cells. Both 
Control testis and tissue exposed to PM, CIS or DOX had morphologically normal tubules, with basement mem-
brane separating tubules from interstitium (Fig. 1). Control cultured testis was healthy, with germ cells situated 
along the basement membrane of the seminiferous tubules. After exposure to Low concentrations of PM, CIS or 
DOX, germ cells could still be observed either at the basement membrane or in the centre of the tubules (Fig. 1B); 
in contrast, it was difficult to identify germ cells after exposure to High concentrations of any of the three drugs, 
after which pyknotic cells were clearly visible and the majority of tubules appeared to contain only Sertoli cells 
(Fig. 1C). Seminiferous tubule diameter decreased in response to Mid (p < 0.01) or High (p < 0.001) levels of CIS 
or DOX, although no decrease was found after exposure to PM (Fig. 2A). Seminiferous tubules containing only 
Sertoli cells were found in less than 10% of Control cultured tubules, but these Sertoli cell-only tubules increased 
markedly in response to all three drugs, until over 95% of tubules lacked germ cells after exposure to the High 
concentrations of each drug (p < 0.001 for all drugs: Fig. 2B).
Expression of mouse vasa homologue (Mvh) was used to identify germ cells using immunohistochemistry 
(IHC), with seminiferous tubules of Control tissue lined by germ cells, many of which were proliferative, as shown 
by incorporation of bromo-2’-deoxyuridine (BrdU; Fig. 3A). In response to exposure to any of the three chemo-
therapeutic agents, there was a marked loss of germ cells from the seminiferous tubules (Fig. 3B,C). Proliferating 
Mvh+ /BrdU+ germ cells were still seen after exposure to the Low concentration of each drug, even amongst the 
small number of germ cells that remained after exposure to Low CIS or Low DOX (Fig. 3B). In contrast, after 
exposure to the High drug concentrations, no Mvh+/BrdU+ dividing germ cells were observed in the High CIS 
or DOX analysis (Fig. 3Cii,iii), and no remaining germ cells at all were seen after exposure to High PM (Fig. 3Ci). 
Counts of Mvh+ cells showed that all three chemotherapeutic drugs induced a significant reduction in germ 
cells after exposure to all concentrations, although this effect was less pronounced after exposure to Low PM 
(p < 0.001): (Fig. 3D). The difference between Control and treatment group germ cell numbers was as follows: 
Low PM 1.5-fold difference, Mid PM 20-fold difference; High PM no Mvh+ cells remaining; Low CIS 40-fold 
difference; Mid/High CIS 500- to 1000-fold difference; Low and Mid DOX 50-fold difference; and High DOX 
100-fold difference. The majority of germ cells were seen to be proliferating (Mvh+/BrdU+), other than where the 
germ cell population had been reduced by 100-fold or more, where few if any proliferating germ cells remained 
(Fig. 3D).
Germ cells were then investigated further, to specifically examine SSCs, since this is the germ cell population 
required for the production of new germ cells and necessary for any subsequent repopulation of depleted sem-
iniferous tubules. IHC was carried out for PLZF, expressed specifically in SSCs, after exposure to Mid PM, Low 
CIS or Low DOX: the Mid PM concentration was used due to the markedly higher survival of germ cells after Low 
www.nature.com/scientificreports/
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PM compared to Low CIS or Low DOX exposure (Fig. 3). As with Mvh+ cells, few PLZF+ SSCs remained after 
exposure to PM, with only occasional SSC cells remaining after exposure to CIS or DOX (Fig. 4).
Somatic cell density is unaffected by cyclophosphamide, cisplatin or doxorubicin. Somatic 
Sertoli and interstitial cells were examined to see if they were also affected by any of the chemotherapy drugs. 
In contrast to the loss of germ cells, Sox9+ Sertoli cells were found lining the seminiferous tubules in all High 
drug-exposed tissues, as in Controls (Fig. 5A–D). Quantification of expression area showed no significant effect 
on the proportion of the tubules occupied by Sertoli cells on exposure to any of the drugs, even at High concen-
trations (Fig. 5E: (i) PM p = 0.54; (ii) CIS p = 0.63; (iii) DOX p = 0.93), with expression area shown to correlate 
closely with manual cell counts (p < 0.0001; Supplementary Figure S2). There is some Sertoli cell proliferation 
during early postnatal development and small numbers of Sox9+/BrdU+ proliferating Sertoli cells were seen in 
Control cultures (Fig. 5A inset) and in all treatment groups, even after exposure to High concentrations of each 
of the three drugs (Fig. 5B–D insets).
Interstitial cells were examined by determining expression of chicken ovalbumin upstream promoter tran-
scription factor II (COUPTFII), expressed in the majority of interstitial cells in the neonatal mouse including 
the cells that will differentiate into adult Leydig stem cells17. The interstitium contained mainly COUPTFII+ 
cells, both in the Control cultured testis and after exposure to each of the chemotherapy drugs, even at High 
Figure 1. Effect of exposure to phosphoramide mustard, cisplatin or doxorubicin on tissue morphology. 
Representative photomicrographs of cultured testis fragments stained with haematoxylin and eosin. (A) Control 
tissue, or after exposure to (B) Low or (C) High concentrations of (i) PM, (ii) CIS or (iii) DOX. Arrows indicate 
germ cells. Scale bars represent 100 µm; scale bars in insets represent 20 µm.
www.nature.com/scientificreports/
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concentrations (Fig. 6A–D). Quantification of expression showed no effect of any drug on the percentage of the 
interstitial area containing COUPTFII+ interstitial cells (Fig. 6E: (i) PM p = 0.55; (ii) CIS p = 0.88; (iii) DOX 
p = 0.15).
Increase in apoptosis and DNA damage in response to exposure to cyclophosphamide, cispla-
tin or doxorubicin. Apoptosis was examined using IHC for cleaved-Caspase-3 (CC3). At the end of the 
culture period, two days after exposure to the chemotherapy drugs had ended, there was relatively little expres-
sion of CC3 in testis exposed to Low concentrations of any of the three drugs (Fig. 6A–D). However, quantifica-
tion of expression within seminiferous tubules showed a significant increase in apoptosis of around 5- to 6-fold 
after exposure to High CIS (p < 0.001) or to Mid or High DOX concentrations (p < 0.01 and 0.001 respectively; 
Fig. 6F). PM-treated tissue did not show significantly different levels of CC3 to Control at any concentration.
Given that an increase in apoptosis might occur only as a more immediate response to the chemotherapy 
drugs, a time course analysis was undertaken. Testis fragments were cultured for 24 h in control medium, and 
then exposed to Mid PM, Low CIS or Low DOX: the Mid PM concentration was used due to the markedly higher 
survival of germ cells after Low PM compared to Low CIS or Low DOX exposure (Fig. 3). As in earlier experi-
ments, drug exposure was for up to 24 h, after which tissue was moved back into drug-free medium. Tissue was 
removed from culture at 8 h intervals, for up to 40 h after the start of drug exposure. IHC was carried out to deter-
mine the level of apoptosis (CC3), and the number of germ cells (Mvh expression). Each of the three chemother-
apy drugs induced a distinct pattern of response (Fig. 7): PM resulted in a significant increase in the amount of 
CC3 16 h after drug-exposure (p < 0.01) followed by a significant decrease in Mvh expression 8 h later, at the 24 h 
time point (p < 0.01); CIS resulted in a significant increase in the amount of CC3 after 24 h (p < 0.01) followed 
by a significant decrease in Mvh expression 8 h later, at the 32 h time point (p < 0.05); in contrast, there was no 
significant effect on CC3 at any time after DOX exposure. Here, Mvh expression was significantly decreased only 
at the 40 h time point (p < 0.001), but this decrease was not preceded by an increase in the amount of CC3. In case 
there was a shorter interval between an increase in the amount of CC3 and germ cell loss compared to the other 
drugs, levels of CC3 at 36 h following DOX-exposure was also investigated: no significant increase in CC3 was 
found at this time point, with the percentage of seminiferous tubule positive for CC3 as follows: mean ± sem of 
Control 0.12 ± 0.02 (n = 8) and DOX-exposed 0.21 ± 0.06 (n = 5); p = 0.14.
Figure 2. Exposure to phosphoramide mustard, cisplatin or doxorubicin results in smaller, and Sertoli cell-only 
seminiferous tubules. (A) Seminiferous tubule diameter; n = 8 for all conditions except high PM where n = 7. 
(B) Percentage of seminiferous tubules that contain only Sertoli cells: (Bi) PM; n = 6–17, (Bii) CIS; n = 5–8, 
(Biii) DOX; n = 11–17. Data are mean + SEM; p < 0.01 (**), p < 0.001 (***) for treatment versus Control.
www.nature.com/scientificreports/
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DNA damage was then investigated by carrying out IHC for phosphorylated, γH2AX, analysing only the high 
intensity foci that occur in response to germ cell damage18–20. Preliminary experiments showed no significant 
change in γH2AX expression eight hours after the start of drug exposure (see Supplementary data S1), so tissue 
was then examined 16 h after exposure to PM, CIS or DOX (Fig. 8). Here, damage was evident after exposure to 
all three drugs (PM p < 0.05; CIS and DOX p < 0.01).
Proliferation within seminiferous tubules is decreased on exposure to cisplatin or doxorubicin 
but not phosphoramide mustard. BrdU was added to the medium for the final 24 h of culture in order 
to examine the proliferative capacity of the tissue following exposure to chemotherapeutics. BrdU incorporation 
Figure 3. Exposure to phosphoramide mustard, cisplatin or doxorubicin results in germ cell loss. (A–C) 
Representative photomicrographs of cultured testis fragments showing immunohistochemical localisation 
of Mvh (red) and BrdU (green), counterstained with DAPI (blue) for (A) Control tissue, or after exposure to 
(B) Low or (C) High concentrations of: (i) PM, (ii) CIS or (iii) DOX. White arrows indicate Mvh+/ BrdU+ 
proliferating germ cells; yellow arrows indicate Mvh+/BrdU− non-proliferating germ cells. (D) Number of 
Mvh+ germ cells (open bars) and Mvh+/ BrdU+ proliferating germ cells (hatched bars) per mm2 of seminiferous 
tubule, after exposure to increasing concentrations of: (Di) PM, (Dii) CIS or (Diii) DOX; n = 8 for all groups. 
White scale bars represent 50 µm; yellow scale bars in insets represent 10 µm. Data are mean + SEM; p < 0.001 
(***) indicate significant differences in Mvh+ germ cells for treatment versus Control.
www.nature.com/scientificreports/
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decreased significantly after exposure to all concentrations of CIS (2-fold; p < 0.001 in each case) or DOX (2-fold 
reduction in response to Low or Mid DOX and 6- to 7-fold reduction in response to High DOX; p < 0.001 in 
each case): in contrast, there was no significant change in BrdU incorporation following PM exposure (p = 0.14; 
Fig. 9A). Separate examination of proliferation within the tubule (Fig. 9B) and interstitial (Fig. 9C) areas showed 
that the difference in proliferation in response to CIS or DOX exposure was primarily due to effects within the 
tubule, while there was no significant effect of CIS or DOX in the interstitium other than in the High DOX treat-
ment group, which exhibited a 3.5-fold decrease in expression (p < 0.01). As with proliferation in the tissue as a 
whole, there was no effect of PM on proliferation within either the tubule or the interstitium.
Discussion
It has long been recognised that chemotherapy treatment can have adverse effects on male reproduction, includ-
ing impairment of subsequent fertility in patients with cancer who are treated prior to puberty, and hence before 
fully functional spermatogenesis9,21. These male childhood cancer patients are particularly important to consider, 
given that prepubertal boys are the one group in which fertility preservation strategies remain experimental at 
the present time1. There is, however, little information on the degree of gonadotoxicity or the specific actions of 
individual chemotherapy drugs. Here, we have examined the effect of three chemotherapy drugs that are com-
monly administered to childhood cancer patients; CYP (through administration of its active metabolite PM), 
CIS and DOX, using a prepubertal mouse in vitro system that has been shown to maintain normal morphological 
appearance of the seminiferous tubules and support the survival and proliferation of the germ and somatic cell 
compartments, with the Control cultured testis tissue similar to that in vivo15. Each of the three drugs induced a 
dramatic loss of germ cells when administered at clinically relevant concentrations, with little effect evident on 
the somatic cell component of the testis.
Culture medium was supplemented with PM, CIS or DOX, with effects of each drug determined across the 
range of concentrations that have been reported in patient serum. PM concentrations used were 0.02 (Low), 0.2 
(Mid) or 2 (High) µg ml−1, equivalent to roughly 0.1 (Low), 1.0 (Mid) or 10 (High) μM, with from 0.1 to 10 μM 
previously found in patient serum22,23. Tissue was exposed to CIS at 0.1 (Low), 0.5 (Mid) or 1 (High) µg ml−1, 
with reported patient serum concentrations from 0.4 to 1 µg ml−1 24,25. Finally, DOX was added to culture medium 
to produce concentrations of 0.05 (Low), 0.1 (Mid) or 0.5 (High) µg ml−1, with reports of 0.01 to 0.6 µg ml−1 in 
patient serum13,26. Whilst it is not possible to determine the concentrations of these drugs that occur within tes-
ticular tissue in vivo, these experiments here do allow comparison of the gonadotoxicity of the different drugs at 
concentrations relative to their circulating levels in patients.
The majority of work examining the effects of chemotherapy drugs on gonadal function in rodents have 
looked at the post-pubertal testis, with exposure to CYP, CIS and DOX all resulting in germ cell damage [for 
example27–31]. However, the adult testis, with fully functional spermatogenesis, is a very different, and more active 
cellular environment than the prepubertal testis, and there is no evidence that results obtained on the former 
tissue can be directly applied to the latter. In contrast to the more extensive literature on adult testis, few reports 
have been published on the effects of chemotherapy drugs on the prepubertal testis. This is despite the fact that 
prepubertal boys cannot yet be offered any fertility preservation method that has been shown to be successful in 
humans, with potential techniques such as testicular tissue transplantation or in vitro development of spermato-
zoa from spermatogonia currently achieved only in animal models32,33.
Figure 4. Exposure to phosphoramide mustard, cisplatin or doxorubicin results in loss of spermatogonial 
stem cells (SSCs). (A,B) Representative photomicrographs of cultured testis fragments from (A) Control 
and (B) treated (PM), with immunohistochemical localization of PLZF (green) to identify SSCs, and of Mvh 
(red) to identify all germ cells; sections are counterstained with DAPI (blue). White arrows indicate PLZF+/
Mvh+ SSCs; yellow arrow indicates PLZF−/Mvh+ non-SSC germ cells. (C) Number of PLZF+ SSCs per mm2 of 
seminiferous tubule after exposure to Mid PM, Low CIS or Low DOX; n = 4–8. Scale bars represent 25 µm. Data 
are mean + SEM; p < 0.05 (*), p < 0.01 (**) for treatment versus Control.
www.nature.com/scientificreports/
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Results here showed that exposure to the Low concentration of PM (the active metabolite of CYP), had less of 
an effect on germ cell numbers than exposure to Low CIS or DOX (1.5 fold compared to 40- and 50-fold respec-
tively), perhaps a surprising result given that the clinical literature indicates that treatment with alkylating agents 
in general, and cyclophosphamide in particular, has the strongest association with fertility problems in males34,35. 
However, for all three drugs, few germ cells remained after exposure to Mid or High concentrations. There has 
been little investigation into the effect of CYP on the prepubertal testis, with no effect reported after in vivo expo-
sure of prepubertal rats36, while the testes of prepubertal mice who were administered CYP were not examined 
until after puberty37. To the best of the authors’ knowledge, there are no publications on laboratory investigations 
into the effects of CIS on the prepubertal testis. Finally, while DOX has previously been considered to be less gon-
adotoxic than CYP or CIS14, the gonadotoxic effects of DOX found on germ cells here are consistent with those 
in prepubertal rats in vivo38,39, and to a study in a prepubertal rat in vitro model using similar concentrations of 
DOX [0.04 and 0.1 µg ml−1;40].
The potential for germ cell repopulation of the seminiferous tubules after chemotherapy-induced loss will 
depend on the survival of proliferative germ cells, specifically those spermatogonia that are stem cells. SSCs are 
necessary both for self-renewal of the germ stem cell population and also for the cellular divisions that support 
the differentiation leading to complete spermatogenesis. A small number of Mvh+/BrdU+ proliferating germ 
cells did remain after Low CIS exposure, but importantly, PLZF-expressing SSCs were rarely seen after exposure 
to Low CIS concentrations. Damage induced by DOX-exposure was at least equivalent to CIS, with PLZF+ SSCs 
Figure 5. Sertoli cell density is unaffected by exposure to phosphoramide mustard, cisplatin or doxorubicin. 
(A–D) Representative photomicrographs of cultured testis fragments showing immunohistochemical 
localisation of Sox9 (green) and BrdU (red), counterstained with DAPI (blue). (A) Control cultured testis 
contains seminiferous tubules lined with Sox9+ Sertoli cells. (B–D) Tissue from High concentration of each 
of: (B) PM, (C) CIS or (D) DOX shows similar expression patterns to Control, including the occurrence of 
proliferating Sertoli cells. White arrows indicate Sox9+/BrdU+ proliferating Sertoli cells. (E) Percentage of 
tubule containing Sox9+ Sertoli cells after exposure to increasing concentrations of: (Ei) PM, (Eii) CIS or (Eiii) 
DOX; n = 8 in all groups except Low and High PM, where n = 7. White scale bars represent 50 µm, yellow scale 
bars in inset represent 10 µm. Data are mean + SEM.
www.nature.com/scientificreports/
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rarely seen even following exposure to Low DOX concentrations, while after exposure to High DOX, no BrdU+ 
proliferative germ cells remained. The situation after PM exposure was more complex: there was less effect on the 
germ cell population as a whole after exposure to lower concentrations, and more PLZF+ SSCs remained after 
Mid PM exposure, but in contrast, High PM exposure was the only treatment group in which no germ cells were 
found. Bearing in mind that experiments here used a short-term in vitro mouse model, our results highlight the 
importance of further work in this area, to directly determine whether SSCs are able to repopulate the seminif-
erous tubules following chemotherapy drug-induced damage, perhaps along with work using human tissue or 
non-human primate models. Overall, results here indicate that the longer term consequences of treatment with 
Figure 6. Apoptosis is increased, but interstitial cell density unaffected, by exposure to phosphoramide 
mustard, cisplatin or doxorubicin. (A–D) Representative photomicrographs of cultured testis fragments 
showing immunohistochemical localisation of COUPTFII (red) and CC3 (green), counterstained with DAPI 
(blue). (A) Control cultured testis shows COUPTFII expression in the majority of interstitial cells, with little 
evidence of apoptosis (CC3-expression). (B–D) Tissue from High concentration of each of: (B) PM, (C) CIS or 
(D) DOX shows similar COUPTFII expression pattern, alongside increasing evidence of apoptosis (CC3+ cells). 
(E) Percentage of interstitium positive for COUPTFII after exposure to increasing concentrations of: (Ei) PM, 
(Eii) CIS or (Eiii) DOX. (F) Percentage of seminiferous tubules positive for CC3 after exposure to increasing 
concentrations of: (Fi) PM, (Fii) CIS or (Fiii) DOX. E,F: n = 8 for all groups except High PM, where n = 7. Scale 
bars represent 50 µm. Data are mean + SEM; p < 0.01 (**), p < 0.001 (***) for treatment versus Control.
www.nature.com/scientificreports/
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CYP are more pronounced at higher concentrations, and that DOX may be as, or even more damaging than CIS, 
with both of these drugs already inducing marked damage at relatively low concentrations. The effects of CYP and 
CIS tie in with clinical findings, but DOX has been considered to have more limited fertility consequences9,21. This 
could reflect the difficulty in determining the gonadotoxicity of individual drugs from clinical studies in which 
patients are treated with complex drug-combinations.
Whilst the present study clearly demonstrate a loss of spermatogonia in the prepubertal rodent testis following 
exposure to chemotherapeutics, including in the PLZF+ SSC population, there are a number of important con-
siderations when extrapolating these findings to human. Similarities between the postnatal day 5 (pnd5) mouse 
and prepubertal human include the fact that the HPG axis is quiescent during this period of development and 
therefore there is no impact of gonadotrophins or of testosterone within the testis5. Whilst in both species, the 
germ cell population consists almost exclusively of spermatogonia4, the spermatogonial sub-populations differ. 
Importantly, in rodents, the Asingle spermatogonia can perform a dual function by acting either as stem cell or 
progenitor, whilst in the human these functions are performed by the Adark and Apale spermatogonial populations 
respectively16. As such, it is important to bear in mind that this could result in differences in sensitivity to chem-
otherapeutics and also in the potential for subsequent recovery. Another important consideration regarding spe-
cies differences in germ cells during this period of development is the rate of spermatogonial proliferation. Whilst 
in rodents there is a relatively high proliferation at pnd5, as demonstrated in the present study, the rate of pre-
pubertal spermatogonial proliferation in humans and non-human primates is relatively low in comparison4,8,41. 
This is of particular relevance in relation to chemotherapy exposures, which often target mitotically active cells.
At the end of the four day culture period, 48 h after the drug exposure period had ended, there was little 
evidence of apoptosis, with significant increases in CC3 expression seen only after exposure to High CIS, or to 
Mid or High DOX, and with no significant increase found after PM exposure. Apoptosis was therefore examined 
in a time-course analysis at 8-h intervals following exposure to each drug, with results showing a difference 
in the response of the prepubertal testis to each of the three drugs. After exposure to PM or CIS, there was 
a similar pattern of a significant increase in apoptosis followed eight hours later by a significant decrease in 
germ cells, although the precise timing of this response differed between the two drugs, occurring earlier fol-
lowing exposure to PM than to CIS. In contrast, no significant increase in CC3 was seen at any time point after 
DOX-exposure, despite the significant decrease in germ cells first seen 40 h after the start of drug-exposure. The 
lack of a significant increase in CC3-expression in response to DOX could have been because increased expres-
sion occurred within the 8 h interval of the time course analysis; however, there was also no effect on CC3 expres-
sion midway through the time interval immediately before the significant effect on germ cells, 36 h after the start 
of DOX-exposure. Given the lack of any increase in CC3 expression in response to DOX exposure, DNA damage 
was investigated by examining expression of phosphorylated H2AX. Phosphorylation of H2AX is one of the ear-
liest responses to double stranded DNA breaks (DSBs), with immunofluorescence analysis of γH2AX showing the 
presence of discrete foci in cell nuclei that have undergone DSBs42. The analysis here investigated only the intense 
foci of expression that are an indicator of germ cell DNA damage18–20, due to the occurrence of low intensity foci 
in healthy male germ cells18,43. Results showed a significant, marked increase in such foci in response to all three 
drugs after 16 h, with DOX exposure leading to the largest increase: CYP and CIS have previously been shown to 
Figure 7. Time course analysis of apoptosis and germ cell loss in response to phosphoramide mustard, cisplatin 
or doxorubicin. Each chemotherapy drug induces a distinct pattern of apoptosis and germ cell loss immediately 
after drug exposure. Histogram of percentage of seminiferous tubules positive for CC3 (upper panel) and Mvh 
(lower panel) across eight-hourly intervals following the start of drug exposure, with tissue exposed to Mid PM, 
Low CIS or Low DOX; n = 4–9. Data are mean + SEM; p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), for treatment 
versus its time-point Control.
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Figure 8. Exposure to phosphoramide mustard, cisplatin or doxorubicin leads to increased expression 
of phosphorylated H2AX. Representative photomicrographs of cultured testis fragments showing 
immunohistochemical localisation of γH2AX (green) of cultured testis tissue collected 16 h after the start of 
drug exposure, counterstained with DAPI (blue). (A) Analysis of γH2AX expression using ImageJ/Fiji software. 
(Ai) Photomicrograph showing cells with high intensity foci (arrow) and with low intensity foci (arrowhead) 
of γH2AX. (Aii) Black and white image of selected areas containing only cells with high intensity foci (arrow), 
after setting a high intensity threshold to exclude cells with low intensity foci (arrowhead) alongside a minimum 
particle size to exclude signals too small to be cells. (Aiii) Image showing the selected areas (black areas in 
Aii) from which pixel intensity is measured to obtain value of integrated density. (B–E) Representative images 
showing γH2AX expression from each group; (B) Control, (C) Mid PM, (D) Low CIS, (E) Low DOX. (F) 
Intensity of γH2AX expression normalised for tubule area; n = 6 in all groups. Scale bars represent 50 µm. Data 
are mean + SEM; p < 0.05 (*), p < 0.001 (***) for treatment versus Control.
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result in an increase in γH2AX in a mouse spermatogonial cell line20. It remains to be seen if the DNA damage 
resulting from DOX exposure leads to apoptosis; or whether the germ cell loss may be the result of a different cell 
death pathway: DOX-induced cardiotoxicity has been shown to result in autophagy44, with senescence reported 
in cell lines45,46.
Despite the marked loss of germ cells, no significant effect was found on either Sertoli (area of Sox9 expres-
sion) or interstitial (area of COUPTFII expression) cell density. It is possible that more subtle damage has been 
induced in either/both somatic cell population(s), the effects of which would not become apparent until later. 
Downstream effects on the somatic cell population of the testis would be expected following germ cell loss: for 
example, absence of germ cells has been shown to alter Sertoli cell gene expression47,48. Alternatively, Sertoli cell 
damage following repeated administration of CIS to adult mice has been shown to result in long-term spermato-
genesis problems despite the survival of stem germ cells49.
Effects of the chemotherapy drugs on proliferation rate in the somatic populations was determined by adding 
BrdU into the culture medium during the last 24 h of culture. There was no effect on proliferation of interstitial 
cells following exposure to any of the drugs (except High DOX). However, there was a highly significant and 
marked decrease in BrdU+ cells within the seminiferous tubules in response to even Low concentrations of CIS 
or DOX, while no such effect was found in response to PM exposure. Given the relatively low rate of proliferation 
and stable density of Sertoli cells in Controls at this stage, the reduction in proliferation is likely to reflect the loss 
of proliferating germ cells. In the human, Sertoli cell proliferation occurs only during the neonatal period and 
Figure 9. Proliferation decreases specifically within tubules after exposure to cisplatin or doxorubicin, but 
not to phosphoramide mustard. (A) Percentage of testis positive for BrdU. This was then examined according 
to (B) percentage of tubule positive for BrdU; and (C) percentage of interstitium positive for BrdU. (A–C) 
Quantification was determined after exposure to increasing concentrations of: (i) PM, (ii) CIS or (iii) DOX; 
n = 8 for all groups. Data are mean + SEM; p < 0.01 (**), p < 0.001 (***) for treatment versus Control.
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following puberty, in contrast to the low level of proliferation that occurs throughout pre-puberty in the mouse. 
Findings here are in contrast with the effect of irradiation on the somatic compartment, which leads to a reduc-
tion in number of Sertoli cells and increase in apoptotis50,51. Moreover further studies are advisable in order to 
assess whether the production of key growth factors and other cytokines are affected by chemotherapy exposure, 
as shown after irradiation52.
In summary, the work here, using an in vitro model of the mouse prepubertal testis, shows that the three 
chemotherapy drugs CYP (through use of its active metabolite PM), CIS and DOX each induced a rapid and 
marked decrease in the germ cell population after exposure to clinically relevant concentrations, and that this 
includes a decrease in the stem germ cell population. CIS and DOX exposure led to a marked drop in germ cell 
numbers even at the lower range of concentrations found in patient serum, while the effect of PM was less pro-
nounced until higher concentrations were used, although High PM was the only treatment that led to a complete 
disappearance of germ cells. The total loss of germ cells in response to High PM alongside the near-disappearance 
of PLZF+ SSCs after exposure to Low concentrations of CIS or DOX, indicate that all three drugs may produce 
long-term reproductive damage. While the effects of CYP/PM and CIS are consistent with effects on fertility 
described in the clinical literature, results here indicate that DOX may have a similar level of gonadotoxicity 
as CYP and CIS. This work used prepubertal mouse testis as the experimental model, and whilst differences 
between rodent and primate testicular development during this period prevent direct translation of the findings 
into human, the present study has identified potentially important information on the effects of chemotherapy 
expsoures that may be used to inform targeted studies in the prepubertal human or non-human primate testis, for 
which tissue is scarce and experimental models are currently lacking.
Methods
Animals. All work was approved by the University of Edinburgh’s Local Ethical Review Committee and car-
ried out in accordance with UK home office regulations. C57Bl/J6 mice were housed in a 14 h light:10 h dark 
photoperiod, with access to food and water ad libitum.
Tissue Culture. Testis tissue was cultured as in Lopes and co-authors15. Testes from a minimum of two pnd5 
mice per culture run were dissected into Leibovitz L-15 dissection medium (Invitrogen, UK) supplemented with 
3 mg ml−1 bovine serum albumin (BSA; Sigma-Aldrich Ltd, UK) at 37 °C and then further dissected into pieces 
of approximately 0.5 mm3. Each piece of testis was transferred onto Whatman Nucleopore membrane (Camlab 
Ltd, UK) floating on 1 ml of α-MEM medium (Invitrogen, UK) supplemented with 10% Knockout Replacement 
Serum (Invitrogen, UK), within a 24-well plate (Greiner Bio-one, UK), and incubated at 37 °C, 5% CO2. Cultures 
were left for 24 h (Day 1).
On Day 2 of culture, medium was supplemented with PM (Niomech, Germany), CIS (Sigma Aldrich, UK) or 
DOX (Sigma Aldrich, UK), with three concentrations per drug chosen to cover the range of reported serum levels 
in patients [PM:22,23; CIS:24,25; DOX:13,26], and with the effect of each drug compared to Control cultures that were 
maintained in drug-free medium throughout. Drugs were dissolved in culture medium to produce final concen-
trations as follows: PM - 0.02 µg ml−1 (Low PM), 0.2 µg ml−1 (Mid PM), or 2 µg ml−1 (High PM); CIS - 0.1 µg ml−1 
(Low CIS), 0.5 µg ml−1 (Mid CIS) or 1 µg ml−1 (High CIS); and DOX - 0.05 µg ml−1 (Low DOX), 0.1 µg ml−1 (Mid 
DOX) or 0.5 µg ml−1 (High DOX) respectively. Due to its volatility, cultures containing PM were placed in sep-
arate culture plates and kept apart from other plates in the incubator53. On Day 3 of culture, membranes were 
transferred into fresh control medium. On the final day of culture (Day 4), medium was additionally supple-
mented with 15 µg ml−1 5- BrdU (Sigma Aldrich Ltd, UK) for subsequent determination of cell proliferation. 
Twenty-four hours later, tissues were fixed for 90 mins in 10% neutral buffered formalin solution (Sigma Aldrich 
Ltd, UK) for IHC or for 60 mins in Bouin’s fluid for histological examination, set in 3% agar (Sigma Aldrich Ltd, 
UK) and embedded in paraffin wax. For each drug, a minimum of 7 testis fragments from each concentration 
were examined, obtained from 2–3 culture runs.
For examination of spermatogonial stem cells (SSC), and for the time-course analysis, tissue was cultured 
either in control medium or exposed to the lowest drug concentration that earlier experiments had shown to 
result in a significant germ cell loss, namely Mid PM, Low CIS or Low DOX (Fig. 3). PLZF (marker of SSC) 
expression was examined after the four day culture period, as above. For the time-course analysis, tissue was 
removed from culture at eight-hourly intervals following the start of drug administration, and then processed as 
above. For each time point, 4–9 testis fragments were analysed, taken from a minimum of 2 culture runs, with 
specific sample sizes as follows: 8 hours - n = 4–5; 16 hours - n = 5–7; 24 hours - n = 5–7; 32 hours - n = 6–9; 
40 hours - n = 5–8. Gamma-H2AX (marker of double-strand DNA breaks) expression was examined after 
16 hours only; n = 6 for all.
Histology. Wax blocks were sectioned at 5 µm, and either taken for IHC (see below) or photomicrographs 
taken of haematoxylin and eosin-stained sections (DMLB Leica microscope, Leica Microsystems Ltd, UK) and 
used for morphological examination by a blind-to-treatment assessor using ImageJ software. In each section, 
the number of seminiferous tubules that lacked visible germ cells on the basement membrane (Sertoli cell-only 
tubules) was noted, and the diameter of every spherical tubule was measured.
Immunohistochemistry. IHC reactions were carried out on one section from the middle of each testis 
fragment. Washes in phosphate-buffered saline (Fisher Scientific UK Ltd, UK) with 0.1% Triton X (PBSTx) were 
performed between each step. Antigen retrieval was performed in 0.01 M citrate buffer (pH6, Sigma Aldrich 
Ltd, UK), followed by blocking step with 20% normal goat serum diluted in PBSTx and 5% w/v BSA for 1 h at 
RT. Slides were incubated with primary antibodies (Table 1) overnight at 4 °C in a humidified environment fol-
lowed by incubation with appropriate secondary antibody and visualisation reagent all at 1:200 dilution (Table 1): 
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specificities of expression patterns were tested by omission of primary or secondary antibodies. Details of all 
double IHCs are given in Table 2. Counterstaining was with 4,6-Diamidino-2-phenylindole (DAPI; Invitrogen, 
UK) at 1:5000 for 10 min and slides were then mounted with Vectashield hard-set mounting medium (Vector 
Laboratories, USA).
Image Acquisition and Analysis. Images were taken using a Leica DM5500B microscope with a 
DFC360FX camera. Image analysis was performed using ImageJ, with the assessor blind to treatment. For anal-
ysis of germ cells and proliferating germ cells, Mvh+/BrdU−, Mvh+/BrdU+ cells and PLZF+ cells were counted 
manually. For all other antibodies excepting γH2AX, each fluorophore area assessed was measured as a percent-
age of the section, tubule or interstitial area, as appropriate: this semi-automated system was verified by com-
parison with manual cell counting (Supplementary Figure S2), similar to results shown previously15. Analysis 
of phosphorylated H2AX expression examined cells with high intensity expression only (Fig. 8A), due to the 
appearance of low intensity γH2AX foci in healthy male germ cells18,43, in contrast to the high intensity foci seen 
in damaged male germ cells18–20. From an initial image showing cells with low and high intensity foci (Fig. 8Ai), a 
high threshold was set in order to analyse only the cells with high intensity foci, alongside setting a minimum par-
ticle size to exclude any signal too small to be a cell. By calculating the intensity values of the pixels only in those 
areas selected in the grayscale image (Fig. 8Aii), the integrated density of γH2AX expression was determined 
(Fig. 8Aiii), with results then normalized for tubule area.
Statistical analysis. For all analyses other than that of the time-course experiment, Minitab software was 
used. Statistical significance of treatment was determined using one-way ANOVA with a general linear mixed 
effect model to take culture run into account. This was followed by Dunnett’s multiple comparisons to compare 
effects of different concentrations with Control. Data from the time-course study were analysed using GraphPad 
Prism. Here, for normally distributed data, one-way ANOVA was performed followed by Dunnett’s post hoc test 
to determine statistical significance between Control and different drug concentrations; for data that were not 
normally distributed, Kruskal-Wallis was performed followed by Dunn’s post hoc test to determine statistical 
significance between Control and different drug concentrations. All results are given as mean ± SEM, with results 
considered statistically significant where p < 0.05.
Data availability. All datasets generated and analysed during the current study are available: datasets used 
for specific figures are in Supplementary data S1; other datasets are available from the corresponding author on 
reasonable request.
Antibody Catalogue# Species Dilution Secondary Antibody Visualisation
BrdU1 ab6326 Rat 1:500 GARat-b5; GARat-5946 Str-4885
CC32 Asp175 Rabbit 1:500 GAR-b5 Str-4885
COUPTFII3 PP-H7147-00 Mouse 1:200 GAM-5687 N/A
γH2AX (phospho S139)1 ab22551 Mouse 1:200 GAM-4888 N/A
Mvh1 ab27591 Mouse 1:100 GAM-5687 N/A
PLZF1 ab189849 Rabbit 1:3000 GAR-4887 N/A
Sox94 AB5535 Rabbit 1:500 GARat-5946 N/A
Table 1. Antibodies and conditions for immunohistochemistry. Abbreviations: GAM-488: Alexafluor Goat 
anti-mouse IgG 488 nm. GAM-568: Alexafluor Goat anti-mouse IgG1 568 nm. GARat-594: Alexafluor Goat 
anti-rat IgG1 594 nm. GAR-488: Alexafluor Goat anti-rabbit IgG 488 nm. GAR-b: Goat anti-rabbit biotinylated. 
GARat-b: Goat anti-rat biotinylated. Companies: 1Abcam, UK; 2Cell Signalling Technology, USA; 3R&D 
systems, USA; 4Millipore, UK; 5Vector Laboratories, USA; 6Invitrogen, UK; 7Life Technologies, UK; 8Molecular 
Probes, Leiden, The Netherlands.
Antigen 1 Dilution
Secondary 
Antibody Visualis- ation Antigen 2 Dilution
Secondary 
Antibody Visualis-ation
CC31 1:500 GAR-b5 Str-4888 Mvh3 1:100 GAM-5686 N/A
COUPTFII2 1:200 GAM-5686 N/A CC31 1:500 GAR-b5 Str-4888
Mvh3 1:100 GAM-5686 N/A BrdU3 1:500 GARat-b5 Str-4888
Sox94 1:500 GARat-5947 N/A BrdU3 1:500 GARat-b5 Str-4888
Table 2. Double immunohistochemistry protocol. Abbreviations: GAM-488: Alexafluor Goat anti-mouse IgG 
488 nm. GAM-568: Alexafluor Goat anti-mouse IgG1 56 nm. GARat-594: Alexafluor Goat anti-rat IgG1 594 nm. 
GAR-488: Alexafluor Goat anti-rabbit IgG 488 nm. GAR-b: Goat anti-rabbit biotinylated. GARat-b: Goat anti-
rat biotinylated. Str-488: Streptavidin 488. Companies: 1Cell Signalling Technology, USA; 2R&D systems, USA; 
3Abcam, UK; 4Millipore, UK; 5Vector Laboratories, USA; 6Life Technologies, UK; 7Invitrogen, UK; 8Molecular 
Probes, Leiden, The Netherlands.
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